AA
DCPH

ALPS Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

ALPS Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,991
Closed -$896K – 1012
2024
Q1 		$896K Buy
56,991
+7,292
+15% +$112K 0.01% 511
2023
Q4 		$802K Sell
49,699
-8,516
-15% -$109K 0.01% 531
2023
Q3 		$740K Buy
58,215
+494
+0.9% +$6.82K 0.01% 542
2023
Q2 		$813K Buy
+57,721
New +$826K 0.01% 529
2020
Q4 		– Sell
-71,891
Closed -$3.69M – 887
2020
Q3 		$3.69M Sell
71,891
-4,306
-6% -$211K 0.05% 177
2020
Q2 		$4.55M Sell
76,197
-22,256
-23% -$1.19M 0.06% 161
2020
Q1 		$4.05M Sell
98,453
-4,368
-4% -$243K 0.06% 158
2019
Q4 		$6.4M Buy
102,821
+5,012
+5% +$238K 0.05% 142
2019
Q3 		$3.32M Buy
97,809
+17,884
+22% +$529K 0.03% 179
2019
Q2 		$1.8M Buy
+79,925
New +$1.87M 0.01% 236

Other funds holding DCPH

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

ALPS Advisors's DCPH Position: Q2 2024 in Review

ALPS Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 56,991 shares — an estimated $896K sold.

ALPS Advisors first reported a position in DCPH in Q2 2019 and held it in 10 quarters. The position peaked at $6.4M in Q4 2019. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • ALPS Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 56,991 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $896K.
  • ALPS Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
  • ALPS Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $6.4M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.